KLK3 and prostate cancer: This study investigated whether the PROSTest, a molecular assay analyzing prostate cancer-specific transcripts, could predict treatment response or prognosis in mCRPC patients receiving docetaxel, compared to changes in prostate-specific antigen (PSA) levels.